User Image Cart Icon 0 Search Image
  • Home > Blog > Reduces Cocaine Self-administration

Reduces Cocaine Self-administration

  1. Pregabalin reduces cocaine self‐administration and relapse to cocaine seeking in the rat
  2. The 5-HT2C receptor agonist lorcaserin reduces cocaine self–administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity
  3. Transcranial magnetic stimulation of medial prefrontal and cingulate cortices reduces cocaine self–administration: a pilot study
  4. Pharmacological stimulation of group ii metabotropic glutamate receptors reduces cocaine self–administration and cocaine-induced reinstatement of drug seeking in …
  5. The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self–administration and reinstatement induced by the stressor yohimbine, and contextual cues
  6. Injection of CART (cocaine-and amphetamine-regulated transcript) peptide into the nucleus accumbens reduces cocaine self–administration in rats
  7. PPL-138 (BU10038): A bifunctional NOP/mu partial agonist that reduces cocaine self–administration in rats
  8. Systemic delivery of a brain-penetrant TrkB antagonist reduces cocaine self–administration and normalizes TrkB signaling in the nucleus accumbens and prefrontal …
  9. Cebranopadol, a mixed opioid agonist, reduces cocaine self–administration through nociceptin opioid and mu opioid receptors
  10. Modified single prolonged stress reduces cocaine self–administration during acquisition regardless of rearing environment
  11. The hypocretin–orexin system regulates cocaine self‐administration via actions on the mesolimbic dopamine system
  12. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self–administration in mice
  13. Potent and selective NOP receptor activation reduces cocaine self‐administration in rats by lowering hedonic set point
  14. Cebranopadol reduces cocaine self–administration in male rats: Dose, treatment and safety consideration
  15. LSP2-9166, an orthosteric mGlu4 and mGlu7 receptor agonist, reduces cocaine self–administration under a progressive ratio schedule in rats
  16. The effects of aerobic exercise on cocaine self–administration in male and female rats
  17. Hypocretin/Orexin regulation of dopamine signaling and cocaine self–administration is mediated predominantly by hypocretin receptor 1
  18. Naltrexone–buprenorphine interactions: effects on cocaine self–administration
  19. Gamma-hydroxybutyric acid decreases intravenous cocaine self–administration in rats
  20. (-)-Stepholidine reduces cue-induced reinstatement of cocaine seeking and cocaine self–administration in rats
  21. Amphetamine maintenance therapy during intermittent cocaine self–administration in rats attenuates psychomotor and dopamine sensitization and reduces addiction …
  22. Hypocretin neurotransmission within the central amygdala mediates escalated cocaine self–administration and stress-induced reinstatement in rats
  23. Doses of GBR12909 that suppress cocaine self‐administration in non‐human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 …
  24. Oxytocin reduces cocaine seeking and reverses chronic cocaine-induced changes in glutamate receptor function
  25. Selective inhibition of M5 muscarinic acetylcholine receptors attenuates cocaine self‐administration in rats
  26. Knockdown of hypocretin attenuates extended access of cocaine self–administration in rats
  27. Cholinergic influence on intravenous cocaine self–administration by rhesus monkeys
  28. Neuroadaptations in the cellular and postsynaptic group 1 metabotropic glutamate receptor mGluR5 and Homer proteins following extinction of cocaine self …
  29. α4β2 Nicotinic receptor desensitizing compounds can decrease self–administration of cocaine and methamphetamine in rats
  30. Ibudilast attenuates cocaine self–administration and prime-and cue-induced reinstatement of cocaine seeking in rats
  31. The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self–administration
  32. The melanin-concentrating hormone system modulates cocaine reward
  33. Reciprocal inhibitory effects of intravenous d-methamphetamine self–administration and wheel activity in rats
  34. Agents in development for the management of cocaine abuse
  35. Group II metabotropic glutamate receptors in the striatum of non-human primates: dysregulation following chronic cocaine self–administration
  36. Withdrawal from cocaine self–administration and Yoked cocaine Delivery Dysregulates Glutamatergic mGlu5 and NMDA Receptors in the Rat Brain
  37. Intermittent cocaine self–administration has sex-specific effects on addiction-like behaviors in rats
  38. cocaine self–administration punished by iv histamine in rat models of high and low drug abuse vulnerability: effects of saccharin preference, impulsivity, and sex
  39. Abstract# 157: Transcranial Magnetic Stimulation of Medial Prefrontal and Cingulate Cortices reduces cocaine self–administration
  40. Effects of chronic buspirone treatment on cocaine self–administration
  41. Risperidone diminishes cocaine-induced craving
  42. Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self–administration in male and female rhesus monkeys.
  43. Effects of cocaine self–administration and its extinction on the rat brain cannabinoid CB1 and CB2 receptors
  44. Overexpression of CREB in the nucleus accumbens shell increases cocaine reinforcement in self-administering rats
  45. Effects of l-methamphetamine treatment on cocaine– and food-maintained behavior in rhesus monkeys
  46. Alternative reinforcer response cost impacts cocaine choice in humans
  47. N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self–administration and cocaine-enhanced brain-stimulation reward in rats
  48. The effects of oral micronized progesterone on smoked cocaine self–administration in women
  49. Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction
  50. The effect of chronic amphetamine treatment on cocaine-induced facilitation of intracranial self-stimulation in rats
  51. Safety and tolerability of intranasal cocaine during phendimetrazine maintenance
  52. #VALUE!
  53. Modulation of cocaine and food self–administration by low-and high-efficacy D1 agonists in squirrel monkeys
  54. Beta-caryophyllene inhibits cocaine addiction-related behavior by activation of PPARα and PPARγ: Repurposing a FDA-approved food additive for cocaine use …
  55. Investigating DAT uptake inhibitors as potential replacement therapies for cocaine
  56. Preclinical research on cocaine self–administration: environmental determinants and their interaction with pharmacological treatment
  57. Effects of progesterone and testosterone on cocaine self–administration and cocaine discrimination by female rhesus monkeys
  58. Differential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on nicotine versus cocaine self–administration and relapse in squirrel monkeys
  59. Ketoconazole increases cocaine and opioid use in methadone maintained patients
  60. Effects of chronic buprenorphine treatment on levels of nucleus accumbens glutamate and on the expression of cocaine-induced behavioral sensitization in rats
  61. Cannabidiol (CBD) reduces cocaine-environment memory in mice
  62. Intermittent access cocaine self–administration produces context-specific escalation and increased motivation
  63. Alprazolam and oxazepam block the cue-induced reinstatement of extinguished cocaine seeking in rats
  64. A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence
  65. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area
  66. Buprenorphine treatment of opiate and cocaine abuse: clinical and preclinical studies
  67. Cannabidiol effects on cocaine-seeking behaviour and incubation of craving in mice
  68. Deletion of the serotonin transporter perturbs BDNF signaling in the central amygdala following long-access cocaine self–administration
  69. Cannabidiol decreases motivation for cocaine in a behavioral economics paradigm but does not prevent incubation of craving in mice
  70. cocaine self–administration and locomotor activity are altered in Lewis and F344 inbred rats by RTI 336, a 3-phenyltropane analog that binds to the dopamine …
  71. self administration of cocaine in monkeys receiving LAAM acutely or chronically
  72. Acamprosate attenuates cocaine-and cue-induced reinstatement of cocaine-seeking behavior in rats
  73. Amphetamine maintenance therapy during intermittent cocaine self–administration in rats: reduction of addiction-like behavior is associated with attenuation of …
  74. Knockdown of Hypocretin/Orexin Attenuates Extended-Access cocaine self–administration in Rats
  75. Behavioral Economic Demand for cocaine During Phendimetrazine Maintenance in Humans
  76. Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms
  77. BP 897, a Selective Dopamine D3 Receptor Ligand with Therapeutic Potential for the Treatment of cocaine‐Addiction
  78. Estradiol as a mechanism for sex differences in the development of an addicted phenotype following extended access cocaine self–administration
  79. GABA mechanisms in the pedunculopontine tegmental nucleus influence particular aspects of nicotine self–administration selectively in the rat
  80. Effects of acupuncture on stress-induced relapse to cocaine-seeking in rats
  81. Augmented acquisition of cocaine self–administration and altered brain glucose metabolism in adult female but not male rats exposed to a cannabinoid …
  82. Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling
  83. Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self …
  84. Hypocretin receptor 1 knockdown in the ventral tegmental area attenuates mesolimbic dopamine signaling and reduces motivation for cocaine
  85. Buprenorphine-induced alterations of cocaine‘s reinforcing effects in rhesus monkey: a dose-response analysis
  86. Addiction-related alterations in D1 and D2 dopamine receptor behavioral responses following chronic cocaine self–administration
  87. Strengthening the accumbal indirect pathway promotes resilience to compulsive cocaine use
  88. Imaging glutamate homeostasis in cocaine addiction with the metabotropic glutamate receptor 5 positron emission tomography radiotracer [11C] ABP688 and …
  89. Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self–administration and food maintained responding in …
  90. Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration
  91. The mGluR2 positive allosteric modulator BINA decreases cocaine self–administration and cue-induced cocaine-seeking and counteracts cocaine-induced …
  92. Clavulanic acid enhances glutamate transporter subtype I (GLT-1) expression and decreases reinforcing efficacy of cocaine in mice
  93. Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self–administration in rats: comparisons with monoamine uptake inhibitors
  94. Hypocretin/Orexin Receptor 1 Knockdown in GABA or Dopamine Neurons in the Ventral Tegmental Area Differentially Impact Mesolimbic Dopamine and …
  95. Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self–administration and subjective responses in humans with cocaine use disorder
  96. BDNF-TrkB controls cocaine-induced dendritic spines in rodent nucleus accumbens dissociated from increases in addictive behaviors
  97. NOP Receptor Agonist Ro 64-6198 decreases escalation of cocaine self–administration in rats genetically selected for alcohol preference
  98. κ-Opioid receptor blockade with nor-binaltorphimine modulates cocaine self–administration in drug-naive rats
  99. Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: a randomized, double blind, placebo-controlled human laboratory …
  100. Effect of the glucocorticoid receptor antagonist PT150 on acquisition and escalation of fentanyl self–administration following early-life stress.
  101. Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep
  102. Effects of lorcaserin on cocaine and methamphetamine self–administration and reinstatement of responding previously maintained by cocaine in rhesus monkeys
  103. Attenuation of cocaine-seeking by progesterone treatment in female rats
  104. Glutamate and reinstatement
  105. Discriminative stimulus effects of cocaine abuse medications in the rhesus monkey
  106. Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use
  107. Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self–administration behavior
  108. Overdose deaths and acute hepatitis infections among American Indians in North Carolina
  109. Effect of novel allosteric modulators of metabotropic glutamate receptors on drug self–administration and relapse: a review of preclinical studies and their clinical …
  110. Effects of the combination of metyrapone and oxazepam on cocaine and food self–administration in rats
  111. Mirtazapine reduces the expression of cocaine-induced locomotor sensitization in male and female Wistar rats
  112. Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats
  113. 5-HT1A autoreceptors in the dorsal raphe nucleus convey vulnerability to compulsive cocaine seeking
  114. Buprenorphine reduces methamphetamine intake and drug seeking behavior via activating nociceptin/orphanin FQ peptide receptor in rats
  115. PPL-103: A mixed opioid partial agonist with desirable anti-cocaine properties
  116. Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self–administration model
  117. Ventral pallidum DRD3 potentiates a pallido-habenular circuit driving accumbal dopamine release and cocaine seeking
  118. Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats
  119. Median and dorsal raphe serotonergic neurons control moderate versus compulsive cocaine intake
  120. Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self–administration after oral administration
  121. Potential role for the hypothalamo–pituitary–adrenal axis in the conditioned reinforcer-induced reinstatement of extinguished cocaine seeking in rats
  122. Modafinil-cocaine interactions: clinical implications
  123. Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self–administration model.
  124. Factors that Affect Social Hierarchy and the Influence of Social Rank and Menstrual Cycle on cocaine self–administration in Female Cynomolgus Monkeys
  125. A preliminary, controlled investigation of magnesium L-aspartate hydrochloride for illicit cocaine and opiate use in methadone-maintained patients
  126. cocaine self–administration, extinction training and drug-induced relapse change metabotropic glutamate mGlu5 receptors expression: Evidence from radioligand …
  127. The 5-HT2C receptor agonist lorcaserin reduces nicotine self–administration, discrimination, and reinstatement: relationship to feeding behavior and impulse …
  128. Dual dopamine/serotonin releasers as potential medications for stimulante and alcohol addictions
  129. Stimulation of medial prefrontal cortex serotonin 2C (5-HT2C) receptors attenuates cocaine-seeking behavior
  130. Effects of the long-acting monoamine reuptake inhibitor indatraline on cocaine self–administration in rhesus monkeys
  131. Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self–administration in rats
  132. Effect of adrenalectomy on cocaine facilitation of lateral hypothalamic self-stimulation
  133. (-)-Stepholidine blocks expression, but not development, of cocaine conditioned place preference in rats
  134. Decrease of cocaine, but not heroin, self–administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats
  135. cocaine and Dysregulated Synaptic Transmission in the Bed Nucleus of the Stria Terminalis
  136. Behavioral and functional evidence of metabotropic glutamate receptor 2/3 and metabotropic glutamate receptor 5 dysregulation in cocaine-escalated rats: factor in …
  137. Metabotropic glutamate receptor 5 activity in the nucleus accumbens is required for the maintenance of ethanol self–administration in a rat genetic model of high …
  138. Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence
  139. Binge-like sucrose self–administration experience inhibits cocaine and sucrose seeking behavior in offspring
  140. Effects of cocaine history on postsynaptic GABA receptors on dorsal raphe serotonin neurons in a stress-induced relapse model in rats
  141. Effect of HD-23, a potent long acting cocaine-analog, on cocaine self–administration in rats
  142. Inhibition of cocaine and 3, 4-methylenedioxypyrovalerone (MDPV) self–administration by lorcaserin is mediated by 5-HT2C receptors in rats
  143. Stimulation of dopamine D2/D3 but not D1 receptors in the central amygdala decreases cocaine-seeking behavior
  144. self‐administration of cocaine and the cocaine analog RTI‐113: Relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus …
  145. The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self–administration and relapse in squirrel monkeys
  146. Effects of escitalopram and imipramine on cocaine reinforcement and drug-seeking behaviors in a rat model of depression
  147. Intra-Accumbal administration of Mecamylamine Reverses the Effects of Cytisine on the Operant Oral self–administration of Ethanol in Rats
  148. The mGluR2 Positive Allosteric Modulator BINA Decreases cocaine self–administration and Cue-Induced cocaine-Seeking…
  149. Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey
  150. Effects of isoflurane anesthesia on addictive behaviors in rats
  151. Interactions between the mGluR2/3 agonist, LY379268, and cocaine on in vivo neurochemistry and behavior in squirrel monkeys
  152. Environmental enrichment and a selective metabotropic glutamate receptor2/3 (mGluR2/3) agonist suppress amphetamine self–administration: Characterizing …
  153. Incubation of cocaine cue reactivity associates with neuroadaptations in the cortical serotonin (5-HT) 5-HT2C receptor (5-HT2CR) system
  154. Nicotine self–administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA
  155. Effects of the mGlu2/3 agonist LY379268 and the mGlu5 antagonist MTEP on ethanol seeking and reinforcement are differentially altered in rats with a history of …
  156. Genetic and pharmacological evidence that 5-HT2C receptor activation, but not inhibition, affects motivation to feed under a progressive ratio schedule of …
  157. α2δ-1 signaling in nucleus accumbens is necessary for cocaine-induced relapse
  158. cocaine-related disorders
  159. Adult hippocampal neurogenesis as a target for cocaine addiction: a review of recent developments
  160. Effects of genetic deletion of endogenous opioid system components on the reinstatement of cocaine-seeking behavior in mice
  161. Imaging glutamate homeostasis in cocaine addiction with the mGluR5 PET radiotracer [11C] ABP688 and Magnetic Resonance Spectroscopy
  162. Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue-and drug-induced fentanyl seeking in rats
  163. The effects of chronic administration of Buprenorphine on intake of heroin and cocaine in rats: behavioral and neurochemical interactions
  164. Cebranopadol blocks the escalation of cocaine intake and conditioned reinstatement of cocaine seeking in rats
  165. Exercise reduces dopamine D1R and increases D2R in rats: implications for addiction
  166. Prefrontal synaptic markers of cocaine addiction-like behavior in rats
  167. A new insight into the role of CART in cocaine reward: involvement of CaMKII and inhibitory G-protein coupled receptor signaling
  168. Impaired extinction of operant cocaine in a genetic mouse model of schizophrenia risk
  169. Metabotropic glutamate group II receptor activation in the ventrolateral dorsal striatum suppresses incentive motivation for cocaine in rats
  170. Effects of acute and chronic ketoconazole administration on hypothalamo–pituitary–adrenal axis activity and brain corticotropin-releasing hormone
  171. Understanding polydrug use: review of heroin and cocaine co‐use
  172. Flipping the main switch in the central reward system?
  173. Effects of d-amphetamine and buprenorphine combinations on speedball (cocaine+ heroin) self–administration by rhesus monkeys
  174. Pair housing does not alter incubation of craving, extinction, and reinstatement after heroin self–administration in female and male rats.
  175. administration of GABAB receptor positive allosteric modulators inhibit the expression of previously established methamphetamine-induced conditioned place …
  176. Rats with extended access to cocaine exhibit increased stress reactivity and sensitivity to the anxiolytic-like effects of the mGluR 2/3 agonist LY379268 during …
  177. Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys.
  178. Nociceptin attenuates the escalation of oxycodone self–administration by normalizing CeA–GABA transmission in highly addicted rats
  179. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects
  180. Theta oscillations in rat infralimbic cortex are associated with the inhibition of cocaine seeking during extinction
  181. The hypodopaminergic state ten years after: transcranial magnetic stimulation as a tool to test the dopamine hypothesis of drug addiction
  182. BDNF as a therapeutic candidate for cocaine use disorders
  183. Metabotropic glutamate receptor 2 positive allosteric modulators: closing the gate on drug abuse?
  184. Multiple faces of BDNF in cocaine addiction
  185. The long-acting D3 partial agonist MC-25-41 attenuates motivation for cocaine in Sprague-Dawley rats
  186. Lorcaserin suppresses oxycodone self–administration and relapse vulnerability in rats
  187. Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.
  188. The dopamine D3 receptor and drug dependence: effects on reward or beyond?
  189. A protocol for measuring cue reactivity in a rat model of cocaine use disorder
  190. Serotonin2C receptors and drug addiction: focus on cocaine
  191. Synergism Between a Serotonin 5-HT2A Receptor (5-HT2AR) Antagonist and 5-HT2CR Agonist Suggests New Pharmacotherapeutics for cocaine Addiction
  192. Dopamine receptor subtypes in reward and relapse
  193. NOP-related mechanisms in substance use disorders
  194. The group II metabotropic glutamate agonist, LY379268, decreases methamphetamine self–administration in rats
  195. Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study
  196. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption
  197. Dual dopamine–5-HT releasers: potential treatment agents for cocaine addiction
  198. CREB activity in dopamine D1 receptor expressing neurons regulates cocaine-induced behavioral effects
  199. Medication-related pharmacological manipulations of nicotine self–administration in the rat maintained on fixed-and progressive-ratio schedules of reinforcement
  200. Glucagon-Like Peptide-1 (GLP-1) and 5-Hydroxytryptamine 2c (5-HT2c) Receptor Agonists in the Ventral Tegmental Area (VTA) Inhibit Ghrelin-Stimulated Appetitive …
  201. Effects of cebranopadol on cocaine-induced hyperactivity and cocaine pharmacokinetics in rats
  202. Neuroadaptive changes in metabotropic glutamate mGlu2/3R expression during different phases of cocaine addiction in rats
  203. The lateral preoptic area: a novel regulator of reward seeking and neuronal activity in the ventral tegmental area
  204. Epigenetic regulation in substance use disorders
  205. Topographic transcriptomics of the nucleus accumbens shell: Identification and validation of fatty acid binding protein 5 as target for cocaine addiction
  206. Metabotropic glutamate group II receptor activation in the dorsal striatum suppresses the motivation for cocaine in rats
  207. Modeling alcohol self–administration in the human laboratory
  208. Effects of lorcaserin on oxycodone self–administration and subjective responses in participants with opioid use disorder
  209. Evidence for a vocal signature in the rat and its reinforcing effects: a key role for the subthalamic nucleus
  210. The individual and combined effects of phenmetrazine and mgluR2/3 agonist LY379268 on the motivation to self-administer cocaine
  211. Evaluating the preclinical validity of cannabinoid therapy for the treatment of psychostimulant use disorder
  212. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human …
  213. D3 Dopamine and Kappa Opioid Receptor Alterations in Human Brain of cocaine‐overdose Victims
  214. Selective serotonin 5-HT2C receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of …
  215. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate
  216. Understanding comorbid ADHD and cocaine abuse: Consequences of adolescent medication in an animal model
  217. Effects of 2β-propanoyl-3β-(4-tolyl)-tropane (PTT) on the self–administration of cocaine, heroin, and cocaine/heroin combinations in rats
  218. New treatments for cocaine dependence: a focused review
  219. Inhibition of N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated …
  220. New medications for drug addiction hiding in glutamatergic neuroplasticity
  221. Environmental, genetic and epigenetic contributions to cocaine addiction
  222. Continuous or intermittent cocaine administration: effects of flupenthixol treatment during withdrawal
  223. Effects of pimavanserin and lorcaserin on alcohol self–administration and reinstatement in male and female rats
  224. The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered
  225. Neuropsychotoxicity of abused drugs: potential of dextromethorphan and novel neuroprotective analogs of dextromethorphan with improved safety profiles in terms of …
  226. Effects of lorcaserin (Belviq®) on nicotine-and food-maintained responding in non-human primates
  227. Assessing addiction vulnerability with different rat strains and place preference procedures: the role of the cocaine and amphetamine-regulated transcript
  228. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?
  229. Novel approaches to the treatment of cocaine addiction
  230. Continuous or intermittent cocaine administration: effects of amantadine treatment during withdrawal
  231. Evaluation of the “pipeline” for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research
  232. Effect of the novel positive allosteric modulator of metabotropic glutamate receptor 2 AZD8529 on incubation of methamphetamine craving after prolonged voluntary …
  233. Dopamine/serotonin releasers as medications for stimulant addictions
  234. The group II metabotropic glutamate receptor agonist, LY379268, decreases methamphetamine self–administration in rats
  235. Functional status of the serotonin 5-HT2C receptor (5-HT2CR) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence
  236. Central GLP-1 receptors: Novel molecular targets for cocaine use disorder
  237. Effects of indatraline and buprenorphine on self–administration of speedball combinations of cocaine and heroin by rhesus monkeys
  238. Microinjection of CART peptide 55–102 into the nucleus accumbens core inhibits the expression of conditioned hyperactivity in a cocaine-associated environment
  239. RTI 113, a 3-phenyltropane analog, produces long-lasting cocaine-like discriminative stimulus effects in rats and squirrel monkeys
  240. Role of mesolimbic ghrelin in the acquisition of cocaine reward
  241. Effects of the monoamine uptake inhibitors RTI-112 and RTI-113 on cocaine-and food-maintained responding in rhesus monkeys
  242. The role of the neurokinin-1 receptor in stress-induced reinstatement of alcohol and cocaine seeking
  243. Sex differences in the neural mechanisms mediating addiction: a new synthesis and hypothesis
  244. Neurobiological basis for the development of cocaine addiction in females: Role of estradiol
  245. Behavioral and functional evidence of mGlu2/3 and mGlu5 metabotropic glutamate receptor dysregulation in cocaine-escalated rats: Factor in the transition to …
  246. Pharmacological approaches to cocaine addiction
  247. GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA
  248. cocaine seeking and taking: role of hippocampal dopamine D1-like receptors
  249. Reward circuitry in addiction
  250. Lipids and addiction: how sex steroids, prostaglandins, and cannabinoids interact with drugs of abuse
  251. Metabotropic glutamate receptor ligands as potential therapeutics for addiction
  252. The Addicted Phenotype: Protein Phosphorylation Status and Dopamine Receptor Responsiveness
  253. Hypocretin receptor 1 involvement in cocaine-associated behavior: therapeutic potential and novel mechanistic insights
  254. Clueless about cues: the impact of reward-paired cues on decision making under uncertainty
  255. The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders
  256. Synthesis of indatraline using a Suzuki cross-coupling reaction and a chemoselective hydrogenation: A versatile approach
  257. Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors
  258. Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys
  259. Feasibility of Exenatide, a GLP-1R Agonist, for Treating cocaine Use Disorder: A Case Series Study
  260. Characterization of methylphenidate self–administration and reinstatement in the rat
  261. Varenicline decreases nicotine but not alcohol self–administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats
  262. Confronting the opioid crisis with basic research in neuropharmacology
  263. Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT2C receptor stimulation and 5-HT2A receptor blockade
  264. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists
  265. Effects of the dopamine reuptake inhibitor PTT on reinstatement and on food-and cocaine-maintained responding in rhesus monkeys
  266. Central injections of noradrenaline induce reinstatement of cocaine seeking and increase c-fos mRNA expression in the extended amygdala
  267. Medication strategies for the management of cocaine use disorder
  268. Acute and chronic interactive treatments of serotonin 5HT2C and dopamine D1 receptor systems for decreasing nicotine self–administration in female rats
  269. The paraventricular thalamic nucleus: a key hub of neural circuits underlying drug addiction
  270. Lesions of the dorsomedial frontal cortex block sensitization to the positive-reinforcing effects of cocaine
  271. Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder
  272. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving
  273. Evaluation of drug abuse treatment medications: concordance between clinical and preclinical studies
  274. Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans
  275. Serotonergic mechanisms in addiction-related memories
  276. GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence
  277. Pharmacokinetic strategies for treatment of drug overdose and addiction
  278. Effects of buprenorphine/lorcaserin mixtures on preference for heroin, cocaine, or saline over food using a concurrent choice procedure in rhesus monkeys
  279. Phentermine pretreatment antagonizes the cocaine-induced rise in mesolimbic dopamine
  280. Effects of co-administration of the GABAB receptor agonist baclofen and a positive allosteric modulator of the GABAB receptor, CGP7930, on the development and …
  281. Dynamic interactions of ceftriaxone and environmental variables suppress amphetamine seeking
  282. cocaine induces paradigm-specific changes to the transcriptome within the ventral tegmental area
  283. CART in energy balance and drug addiction: current insights and mechanisms
  284. Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats
  285. Neuroplastic alterations in the limbic system following cocaine or alcohol exposure
  286. The inhibition of cocaine-induced locomotor activity by CART 55-102 is lost after repeated cocaine administration
  287. Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core
  288. Mesolimbic dopamine signaling in cocaine addiction
  289. Agonist replacement therapy for cocaine dependence: a translational review
  290. Benztropine pretreatment does not affect responses to acute cocaine administration in human volunteers
  291. Comparative behavioral pharmacology of cocaine and the selective dopamine uptake inhibitor RTI-113 in the squirrel monkey
  292. Discriminative stimulus effects of dopaminergic agents in rhesus monkeys
  293. Effects of the 5-HT2C receptor agonist CP809101 in the amygdala on reinstatement of cocaine-seeking behavior and anxiety-like behavior
  294. Repeated 7-day treatment with the 5-HT2C agonist lorcaserin or the 5-HT2A antagonist pimavanserin alone or in combination fails to reduce cocaine vs food …
  295. Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue-and drug-induced heroin seeking in high drug-taking rats
  296. Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence
  297. Effects of single and dual administration of cocaine and ethanol on opioid and ORL1 receptor expression in rat CNS: an autoradiographic study
  298. CXCL12/CXCR4 signaling in mesocorticolimbic reward pathways: relevance to cocaine reinforcement and relapse
  299. AMPA receptor synaptic plasticity induced by psychostimulants: the past, present, and therapeutic future
  300. Design and Synthesis of Systemically Active Metabotropic Glutamate Subtype-2 and -3 (mGlu2/3) Receptor Positive Allosteric Modulators (PAMs): Pharmacological …
  301. Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin seeking behavior in rats
  302. Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys by direct and indirect activation of 5-HT2C receptors
  303. Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys
  304. Metabotropic glutamate receptor 7 (mGluR7) as a target for the treatment of psychostimulant dependence
  305. Clinical potential of a rationally engineered enzyme for treatment of cocaine dependence: Long-lasting blocking of the psychostimulant, discriminative stimulus, and …
  306. Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction
  307. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders
  308. Oxycodone self–administration and withdrawal behaviors in male and female Wistar rats
  309. Increases in compulsivity, inflammation, and neural injury in HIV transgenic rats with escalated methamphetamine self–administration under extended-access …
  310. Effects of the serotonin 2C receptor agonist WAY163909 on the abuse-related effects and mesolimbic dopamine neurochemistry induced by abused stimulants in …
  311. Metabotropic glutamate receptors 2 and 3 as targets for treating nicotine addiction
  312. Substituted 1-Phenyl-3-(pyridin-2-yl)urea Negative Allosteric Modulators of mGlu5: Discovery of a New Tool Compound VU0463841 with Activity in Rat Models of …
  313. Group II metabotropic glutamate receptors (mGlu2/3) in drug addiction
  314. The influence of stress on the transition from drug use to addiction
  315. Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1
  316. self–administration of drugs of abuse
  317. Considerations in the evaluation of potential efficacy of medications for alcohol and drug use disorders: an editorial
  318. Serotonin2C receptors in the medial prefrontal cortex facilitate cocaine-induced dopamine release in the rat nucleus accumbens
  319. GIRK3 gates activation of the mesolimbic dopaminergic pathway by ethanol
  320. Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats
  321. Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels
  322. Effects of the mGluR2/3 receptor agonist LY379268 on the reinforcing strength of cocaine in rhesus monkeys
  323. Antagonizing 5-HT2A receptors with M100907 and stimulating 5-HT2C receptors with Ro60-0175 blocks cocaine-induced locomotion and zif268 mRNA expression in …
  324. Sex differences in selecting between food and cocaine reinforcement are mediated by estrogen
  325. Intermittent intake of rapid cocaine injections promotes robust psychomotor sensitization, increased incentive motivation for the drug and mGlu2/3 receptor …
  326. Role of the glutamatergic system in nicotine dependence: implications for the discovery and development of new pharmacological smoking cessation therapies
  327. Reduced ethanol consumption and preference in cocaine‐and amphetamine‐regulated transcript (CART) knockout mice
  328. A single cocaine administration alters dendritic spine morphology and impairs glutamate receptor synaptic retention in the medial prefrontal cortex of adolescent rats
  329. Using glutamate homeostasis as a target for treating addictive disorders
  330. rTMS reduces psychopathological burden and cocaine consumption in treatment-seeking subjects with cocaine use disorder: an open label, feasibility study
  331. Contributions of serotonin in addiction vulnerability
  332. Transcriptional and epigenetic regulation of reward circuitry in drug addiction
  333. Serotonin and Reward-Related Behavior: Focus on 5-HT2C Receptors
  334. mGlu5 receptors: neuroanatomy, pharmacology, and role in drug addiction
  335. Exercise and substance abuse
  336. Glutamate neurotransmission in the course of cocaine addiction
  337. Non-invasive brain stimulation in substance use disorders: implications for dissemination to clinical settings
  338. Street-Wise Crack Research: Like earlier students of tribal culture, modern ethnographers live and work with” crack families” in the toughest neighborhoods of New …
  339. Repeated cocaine exposure prior to fear conditioning induces persistency of PTSD-like symptoms and enhancement of hippocampal and amygdala cell density in …
  340. The GABA-B antagonist 2-hydroxysaclofen reverses the effects of baclofen on the discriminative stimulus effects of D-amphetamine in the conditioned taste aversion …
  341. Heightened cocaine-seeking in male rats associates with a distinct transcriptomic profile in the medial prefrontal cortex
  342. Opposing Spatially Segregated Function of Endogenous GDNF-RET Signaling in cocaine Addiction
  343. CART peptide in the nucleus accumbens shell acts downstream to dopamine and mediates the reward and reinforcement actions of morphine
  344. Intermittent access training produces greater motivation for a non-drug reinforcer than long access training
  345. Critical involvement of 5-HT2C receptor function in amphetamine-induced 50-kHz ultrasonic vocalizations in rats
  346. Ventral tegmental area afferents and drug-dependent behaviors
  347. Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake …
  348. Trace Amine-Associated Receptor 1 and cocaine Abuse
  349. Serotonin receptors as potential targets for modulation of nicotine use and dependence
  350. Lipid transmitter signaling as a new target for treatment of cocaine addiction: new roles for acylethanolamides and lysophosphatidic acid
  351. Intraaccumbens baclofen selectively enhances feeding behavior in the rat
  352. CART peptides: regulators of body weight, reward and other functions
  353. The combination of metyrapone and oxazepam for the treatment of cocaine and other drug addictions
  354. Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy
  355. The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys
  356. Imidazenil, a positive allosteric GABAA receptor modulator, inhibits the effects of cocaine on locomotor activity and extracellular dopamine in the nucleus accumbens …
  357. cocaine use disorder: a look at metabotropic glutamate receptors and glutamate transporters
  358. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors
  359. HPA axis-interaction with behavioral systems
  360. The role of the serotonin transporter in prefrontal cortex glutamatergic signaling following
  361. Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders
  362. From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders
  363. Anti-relapse medications: preclinical models for drug addiction treatment
  364. Interactions of glutamatergic neurotransmission and brain-derived neurotrophic factor in the regulation of behaviors after nicotine administration
  365. A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats
  366. Accumbens volumes are reduced among crack-cocaine users
  367. Medication take-home doses and contingency management.
  368. Acute Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Prevents Cue-, Stress-and Drug-Induced Heroin Seeking in Rats
  369. Neurobiology of substance use disorders
  370. Sex differences and addiction
  371. Neurochemical adaptations and cocaine dependence
  372. Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys
  373. Activation of the amylin pathway modulates cocaine-induced activation of the mesolimbic dopamine system in male mice
  374. Ethical issues raised by proposals to treat addiction using deep brain stimulation
  375. A functional inhibitory role of habenular glucagon-like peptide-1 (GLP-1) in forebrain reward signaling
  376. BETHANY R. BROOKSHIRE
  377. H3K4 dimethylation at FosB promoter in the striatum of chronic stressed rats promotes morphine-induced conditioned place preference
  378. The role of neuropeptide CART in the lateral hypothalamic-ventral tegmental area (LH-VTA) circuit in motivation
  379. Interaction between noradrenaline and corticotrophin-releasing factor in the reinstatement of cocaine seeking in the rat
  380. Mecamylamine: new therapeutic uses and toxicity/risk profile
  381. Interaction between cocaine use and sleep behavior: a comprehensive review of cocaine‘s disrupting influence on sleep behavior and sleep disruptions …
  382. The neural basis of addiction: a pathology of motivation and choice
  383. Biphasic reward effects are characteristic of both lorcaserin and drugs of abuse: implications for treatment of substance use disorders
  384. Introduction to the Special Issue:“Making orexin-based therapies for addiction a reality: What are the steps from here?”
  385. Drug dependence as a disorder of neural plasticity: focus on dopamine and glutamate
  386. The hypothalamic-pituitary-adrenal axis and addiction
  387. The role of 5-HT2a/2c receptors in nociception and opioid antinociception: A review of the preclinical literature
  388. Neurosteroids and Addictive Pathology
  389. Impact of social stress in addiction to psychostimulants: what we know from animal models
  390. A review on the role of metabotropic glutamate receptors in neuroplasticity following psychostimulant use disorder
  391. Differential effects of blockade of dopamine D1-family receptors in nucleus accumbens core or shell on reinstatement of heroin seeking induced by contextual and …
  392. Appetite suppressants as agonist substitution therapies for stimulant dependence
  393. Abstract# 155: Individualized connectivity between rTMS targets and the subgenual cingulate is unrelated to antidepressant response
  394. γ-Aminobutyric acid mimetic drugs differentially inhibit the dopaminergic response to cocaine
  395. NOP agonist action of cebranopadol counteracts its liability to promote physical dependence
  396. cocaine-and amphetamine-regulated transcript (CART): a multifaceted neuropeptide
  397. Nr4a1 suppresses cocaine-induced behavior via epigenetic regulation of homeostatic target genes
  398. Recent developments in the behavioural and pharmacological enhancement of extinction of drug seeking
  399. Clinical pharmacology and toxicology of cocaine
  400. 3, 4-methylenedioxypyrovalerone high-responder phenotype as a tool to evaluate candidate medications for stimulant use disorder
  401. Action of cocaine involves depletion of dopaminergic and serotonergic storage vesicles
  402. Context-induced relapse to drug seeking: a review
  403. Critical assessment of how to study addiction and its treatment: human and non-human animal models
  404. The Pharmacology of an Agonist Medication to Treat Stimulant Use Disorder
  405. PYY3-36 infused systemically or directly into the VTA attenuates fentanyl seeking in male rats
  406. Abstract# 156: Functional connectivity changes with targeted rTMS of the dorsal attention network in TBI-associated depression
  407. Regulation of dynorphin gene expression by κ-opioid agonist treatment
  408. Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of …
  409. Stress and relapse to cocaine seeking in the rat: Effects of post-stress delay periods and influence of environmental context
  410. Possible mechanisms underlying the effects of glucagon-like peptide-1 receptor agonist on cocaine use disorder
  411. Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs
  412. Cross-talk between the HPA axis and addiction-related regions in stressful situations
  413. CART peptides and drugs of abuse: a review of recent progress
  414. Compulsive methamphetamine taking in the presence of punishment is associated with increased oxytocin expression in the nucleus accumbens of rats
  415. Dopamine receptor subtype agonists and feeding behavior
  416. Type 4 phosphodiesterases and drug conditioned reward in mice
  417. The role of noradrenaline and 5-hydroxytryptamine in yohimbine-induced increases in alcohol-seeking in rats
  418. Anticocaine catalytic antibodies have no affinity for RTI compounds: implications for treatment
  419. Maintenance of conditioned place preferences and aversion in C57BL6 mice: effects of repeated and drug state testing
  420. cocaine and inhibition of nitric oxide synthesis produce opioid-mediated antinociception
  421. Alpha-2 Adrenergic Receptors in Alcohol self–administration and Relapse in Rats: Role of Alcohol Dependence and Sex
  422. 6.3 NEUROCHEMICAL ADAPTATIONS AND cocaine DEPENDENCE
  423. Evidence-based treatments of addiction
  424. Neurochemical mechanisms of phentermine and fenfluramine: therapeutic and adverse effects
  425. Cannabidiol prevents several of the behavioral alterations related to cocaine addiction in mice
  426. Intermittent theta burst stimulation of the prefrontal cortex in cocaine use disorder: a pilot study
  427. Effects of metabotropic glutamate receptor ligands on male sexual behavior in rats
  428. Extended access to oxycodone self–administration produces hyperalgesia and irritability-like behavior in male and female rats.
  429. Pre-clinical anti-addictive and side-effect profiles of novel kappa-opioid agonists
  430. Neurotrophins in the ventral tegmental area: Role in social stress, mood disorders and drug abuse
  431. Cortical and subthalamic circuits in the regulation of addiction-like behaviors
  432. Nicotinic receptors differentially modulate the induction and expression of behavioral sensitization to methylphenidate in rats
  433. Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking
  434. Hunger and satiety gauge reward sensitivity
  435. G protein‐coupled receptor modulation of striatal dopamine transmission: Implications for psychoactive drug effects
  436. Neurobehavioral effects of environmental enrichment and drug abuse vulnerability: An updated review
  437. Environmental Enrichment and the Effects on Drug Abuse Vulnerability: The Last Ten Years
  438. Intraperitoneal administration of CART 55–102 inhibits psychostimulant-induced locomotion
  439. Gut-brain axis and addictive disorders: A review with focus on alcohol and drugs of abuse
  440. The relationship between feeding and drug-seeking behaviors
  441. Acute Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Prevents Drug-Induced Heroin Seeking in Rats
  442. G protein-coupled receptor modulation of striatal dopamine transmission: Implications for substance use disorders
  443. Increases in compulsivity, inflammation, and neural injury in HIV transgenic rats with escalated methamphetamine self–administration under extended-access …
  444. Endogenous glucagon-like peptide-1 receptor signaling in the nucleus tractus solitarius is required for food intake control
  445. Microinjection of the mGluR2/3 agonist, LY379268, into the nucleus accumbens attenuates extinction latencies and the reinstatement of morphine-induced …
  446. 5 CHAPTER Neurochemical Adaptations and cocaine Dependence
  447. Effects of linagliptin on morphine dependence in larval zebrafish ()
  448. Drugs currently in Phase II clinical trials for cocaine addiction
  449. Functional profile of systemic and intrathecal cebranopadol in nonhuman primates
  450. Priming with BTCP, a dopamine reuptake blocker, reinstates cocaine-seeking and enhances cocaine cue-induced reinstatement
  451. cocaine, β-Endorphin, and δ-Opioid Receptors
  452. Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents
  453. Novel Pharmacological Agents for the Treatment of cocaine Use Disorder
  454. Role of melanin-concentrating hormone in drug use disorders
  455. The neurobiology of addiction
  456. Evidence-based treatments of addiction.
  457. The winding road to relapse: forging a new understanding of cue-induced reinstatement models and their associated neural mechanisms
  458. Escalated (Dependent) Oxycodone self–administration Is Associated with Cognitive Impairment and Transcriptional Evidence of Neurodegeneration in …
  459. Reward loss and addiction: Opportunities for cross-pollination
  460. Environmental enrichment alleviates cognitive and psychomotor alterations and increases adult hippocampal neurogenesis in cocaine withdrawn mice
  461. Hippocampal-dependent inhibitory learning and memory processes in the control of eating and drug taking
  462. PICK1-deficient mice exhibit impaired response to cocaine and dysregulated dopamine homeostasis
  463. Stressing the other paraventricular nucleus
  464. Clinical and functional connectivity outcomes of 5-Hz repetitive transcranial magnetic stimulation as an add-on treatment in cocaine use disorder: a double-blind …
  465. Abuse liability assessment for biologic drugs–All molecules are not created equal
  466. The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats
  467. Hennepin County Medical Center and University of Minnesota
  468. Neurobiology of stimulants.
  469. Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside
  470. Prenatal buprenorphine exposure and sexually dimorphic nonreproductive behaviors in rats
  471. Traditional medicine in the treatment of drug addiction
  472. cocaine-and amphetamine-regulated transcript in the nucleus accumbens shell attenuates context-induced reinstatement of alcohol seeking.
  473. Vulnerability to addiction
  474. The role of hypocretin in driving arousal and goal-oriented behaviors
  475. Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats
  476. Abuse potential of pregabalin: a systematic review
  477. Cebranopadol as a Novel Promising Agent for the Treatment of Pain
  478. Neuroinflammatory response in reward-associated psychostimulants and opioids: a review
  479. Role of dopamine D1-family receptors in dorsolateral striatum in context-induced reinstatement of heroin seeking in rats
  480. Efficacy of high-frequency (15 Hz) repetitive transcranial magnetic stimulation (rTMS) of the left premotor cortex/dorsolateral prefrontal cortex in decreasing cocaine …
  481. Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice
  482. cocaine and amphetamine related transcript (CART) inhibits context induced reinstatement of reward seeking.
  483. The Potential Role of Dopaminergic Neuromodulation in Adolescence
  484. Effects of a glucagon-like peptide-1 analog on appetitive and consummatory behavior for rewarding and aversive gustatory stimuli in rats
  485. RTI-76, an irreversible inhibitor of dopamine transporter binding, increases locomotor activity in the rat at high doses
  486. Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases
  487. Neuronal nicotinic acetylcholine receptors in reward and addiction
  488. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies
  489. Activity-dependent epigenetic remodeling in cocaine use disorder
  490. Norepinephrine as a Therapeutic Target for cocaine Use Disorder
  491. The role of the metabotropic glutamate 5 and adenosine 2A receptors in methamphetamine addiction
  492. Repeated cocaine exposure dysregulates BDNF expression and signaling in the mesocorticolimbic pathway of the adolescent rat
  493. The neurosteroid dehydroepiandrosterone sulfate, but not androsterone, enhances the antidepressant effect of cocaine examined in the forced swim test—possible …
  494. New directions in medication-facilitated behavioral treatment for substance use disorders
  495. Glutamatergic transmission in drug reward: implications for drug addiction
  496. Neurorobiology and evidence-based biological treatments for substance abuse disorders
  497. #VALUE!
  498. Treatment of co-occurring alcohol and other drug use disorders
  499. Evaluation of the conditioned reinforcing effects of phentermine and fenfluramine in the rat: concordance with clinical studies
  500. Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents
  501. The Gut-Brain Axis and Addictions: A New Narrative
  502. How addictive are gabapentin and pregabalin? A systematic review
  503. Attenuation of morphine dependence and withdrawal in rats by venlafaxine, a serotonin and noradrenaline reuptake inhibitor
  504. Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic
  505. Preclinical Evidence for Intersectional Impacts of HIV and cocaine Use Disorders on Behavior and Neuroimmune Function
  506. Pharmacological and genetic interventions in serotonin (5-HT) 2C receptors to alter drug abuse and dependence processes
  507. Effect of the novel positive allosteric modulator of mGluR2 AZD8529 on incubation of methamphetamine craving after prolonged voluntary abstinence in a rat …
  508. Linagliptin, a selective dipeptidyl peptidase-4 inhibitor, reduces physical and behavioral effects of morphine withdrawal
  509. Contribution of a mesocorticolimbic subcircuit to drug context-induced reinstatement of cocaine-seeking behavior in rats
  510. Inhibitory actions of mGlu4 receptor ligands on cocaine-, but not nicotine-, induced sensitizing and conditioning locomotor responses in rats
  511. Metabotropic glutamate receptors as targets for the treatment of drug and alcohol dependence
  512. Depletion of serotonin decreases the effects of the kappa-opioid receptor agonist U-69593 on cocaine-stimulated activity
  513. Brain site-specific inhibitory effects of the GLP-1 analogue exendin-4 on alcohol intake and operant responding for palatable food
  514. Regulation of cocaine-induced behaviors and anxiety produced by cocaine withdrawal through the serotonin 2C (5-HT2C) receptor
  515. The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?
  516. 2006 NATHAN B. EDDY MEMORIAL AWARD LECTURE
  517. Role of dorsal medial prefrontal cortex dopamine D1-family receptors in relapse to high-fat food seeking induced by the anxiogenic drug yohimbine
  518. Exercise as treatment for substance abuse
  519. Inhibition of experimental visceral pain in rodents by cebranopadol
  520. Lesions of the ventral tegmental area disrupt drug-induced appetite stimulating effects but spare reward comparison
  521. Addiction III: From mouse to man
  522. GRADUATE STUDENTS/POSTDOCTORAL FELLOWS
  523. Transcranial magnetic stimulation for the treatment of cocaine addiction: A systematic review
  524. The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens
  525. Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets
  526. Abstract# 154: Epidural Anesthesia to Effectively Manage Pain and Facilitate Rehabilitation in a Pediatric Case of CRPS
  527. Role of nociceptin/orphanin FQ-NOP receptor system in the regulation of stress-related disorders
  528. Role of GABAA receptors in dorsal raphe nucleus in stress-induced reinstatement of morphine-conditioned place preference in rats
  529. Anhedonic-like behavior and BDNF dysregulation following a single injection of cocaine during adolescence
  530. Dopamine receptor partial agonists and addiction
  531. Preference for palatable food, impulsivity, and relation to drug addiction in rats
  532. The Neuropsychoendocrinology of Substance Use Disorders
  533. Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and …
  534. Choice between delayed food and immediate opioids in rats: treatment effects and individual differences
  535. Gut peptide regulation of food intake–evidence for the modulation of hedonic feeding
  536. Stress, anxiety, and cocaine abuse
  537. Increased temporal discounting after chronic stress in CHL1-deficient mice is reversed by 5-HT2C agonist Ro 60-0175
  538. rTMS-induced changes in glutamatergic and dopaminergic systems: relevance to cocaine and methamphetamine use disorders
  539. Activation of ventral tegmental area 5-HT2C receptors reduces incentive motivation
  540. A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence
  541. Crosstalk between opioid and anti-opioid systems: An overview and its possible therapeutic significance
  542. Serotonergic systems in the pathophysiology of ethanol dependence: relevance to clinical alcoholism
  543. Saccharin preference in rats: relation to impulsivity and drug abuse
  544. Cebranopadol: A novel first-in-class potent analgesic acting via NOP and opioid receptors
  545. Pharmacological modulation of 5-HT2C receptor activity produces bidirectional changes in locomotor activity, responding for a conditioned reinforcer, and …
  546. Serotonin2C receptor stimulation inhibits cocaine-induced Fos expression and DARPP-32 phosphorylation in the rat striatum independently of dopamine outflow
  547. An overview of appetite-regulatory peptides in addiction processes; from bench to bed side
  548. Activation of group II metabotropic glutamate receptors inhibits the discriminative stimulus effects of alcohol via selective activity within the amygdala
  549. Allosteric modulation of metabotropic glutamate receptors
  550. Reinstatement of cocaine seeking in rats by the pharmacological stressors, corticotropin-releasing factor and yohimbine: role for D1/5 dopamine receptors
  551. Nicotine regulates cocaine‐amphetamine‐Regulated Transcript (Cart) in the mesocorticolimbic system
  552. Metabotropic glutamate receptors: from the workbench to the bedside
  553. Kappa opioid receptor activation in the nucleus accumbens inhibits glutamate and GABA release through different mechanisms
  554. Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens
  555. Development of allosteric modulators of GPCRs for treatment of CNS disorders
  556. Contributions of non-human primates to the understanding of cocaine addiction
  557. Amantadine treatment for cocaine-dependent patients with severe withdrawal symptoms
  558. DeepREAL: a deep learning powered multi-scale modeling framework for predicting out-of-distribution ligand-induced GPCR activity
  559. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction
  560. Involvement of noradrenergic neurotransmission in the stress-but not cocaine-induced reinstatement of extinguished cocaine-induced conditioned place …
  561. The effect of the mGlu8 receptor agonist,(S)-3, 4-DCPG on acquisition and expression of morphine-induced conditioned place preference in male rats
  562. Transcranial magnetic stimulation: a review about its efficacy in the treatment of alcohol, tobacco and cocaine addiction
  563. The lateral preoptic area regulates the ventral tegmental area and drives reinforcement and aversion
  564. Misuse and abuse of pregabalin and gabapentin: cause for concern?
  565. Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders
  566. Progress report from the testing program for stimulant and depressant drugs (1998)
  567. Regional influence of cocaine on evoked dopamine release in the nucleus accumbens core: A role for the caudal brainstem
  568. Yohimbine, but not footshock stress, reinstates heroin seeking in the presence of a discriminative, drug-predictive cue
  569. A critical role of nucleus accumbens dopamine D1-family receptors in renewal of alcohol seeking after punishment-imposed abstinence.
  570. The orexin 1 receptor modulates kappa opioid receptor function via a JNK-dependent mechanism
  571. Drug addiction co-morbidity with alcohol: Neurobiological insights
  572. LSD1-BDNF activity in lateral hypothalamus-medial forebrain bundle area is essential for reward seeking behavior
  573. Long-term outcome of repetitive transcranial magnetic stimulation in a large cohort of patients with cocaine-use disorder: an observational study
  574. Age-and sex-specific effects of amphetamines on cognition and serotonin in the orbitofrontal cortex
  575. Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese population
  576. Action-outcome expectancies require orbitofrontal neurotrophin systems in naïve and cocaine-exposed mice
  577. Regulation of cocaine-induced reinstatement by group II metabotropic glutamate receptors in the ventral tegmental area
  578. The involvement of nicotinic cholinergic receptors in drug abuse
  579. Neural basis of pleasure and reward
  580. Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse
  581. 2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy
  582. Individual differences in the improvement of cocaine-induced place preference response by the 5-HT2C receptor antagonist SB242084 in rats
  583. Regional Effects of cocaine on Phasic Dopamine Release in the Nucleus Accumbens: A Role for the Hindbrain
  584. Modafinil blocks reinstatement of extinguished opiate-seeking in rats: mediation by a glutamate mechanism
  585. cocaine and amphetamine related transcript (CART) inhibits context induced reinstatement of reward seeking
  586. Glucagon-like peptide-1 and alcohol-mediated behaviors in rodents
  587. Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits
  588. Cigarette smoking and short-term addiction treatment outcome
  589. Influence of local and circuit-wide modulation of the mesocorticolimbic reward system on the reinstatement of cocaine seeking
  590. Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in …
  591. SYMPOSIUM XI CPDD: CHEMISTRY TO PHARMACOLGY: DRUGS AND DEPENDENCE
  592. Differences in the structure of drinking, cart expression and dopamine turnover between polydipsic and non polydipsic rats in the quinpirole model of psychotic …
  593. Brain and cognition for addiction medicine: From prevention to recovery neural substrates for treatment of psychostimulant-induced cognitive deficits
  594. Drugs currently in Phase II clinical trial for cocaine addiction
  595. Effect of cocaine and Ethanol on the glutamatergic system
  596. Regulation of cocaine-induced Behaviors and Anxiety Produced by cocaine Withdrawal through the Serotonin (2C) Receptor
  597. The NOP receptor system in neurological and psychiatric disorders: discrepancies, peculiarities and clinical progress in developing targeted therapies
  598. Intracerebroventricular CART peptide reduces food intake and alters motor behavior at a hindbrain site
  599. Attenuation of cocaine-induced conditioned locomotion is associated with altered expression of hippocampal glutamate receptors in mice lacking LPA1 receptors
  600. Brain opioid mechanisms in amphetamine induced behaviours
  601. κ2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims
  602. Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review
  603. Development of a highly efficient long-acting cocaine hydrolase entity to accelerate cocaine metabolism
  604. Identifying roles for peptidergic signaling in mice
  605. A single cocaine administration alters dendritic spine morphology and impairs glutamate
  606. The role of serotonin in memory: interactions with neurotransmitters and downstream signaling
  607. Turn the next page: Envisioning the future of addiction therapeutics.
  608. cocaine‐and amphetamine‐regulated transcript peptide in the nucleus accumbens shell inhibits cocaine‐induced locomotor sensitization to transient over …
  609. The role of dopamine receptors and inhibitory G proteins in stimulant and opioid reinforcement
  610. The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review
  611. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil
  612. Targeting the 5-HT2C receptor in biological context and the current state of 5-HT2C receptor ligand development
  613. Glutamatergic transmission in drug reward: implications for drug addiction (2015)
  614. Insulin and fluoxetine produce opposite actions on lateral septal nucleus–infralimbic region connection responsivity
  615. Clinical Off-Label Use of Deep Transcranial Magnetic Stimulation in Psychiatric Conditions
  616. Effects of 5-HT2C receptor stimulation in male mice on behaviour and Fos expression: Feeding, reward and impulsivity
  617. The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice
  618. Gender does not matter: add-on repetitive transcranial magnetic stimulation treatment for female methamphetamine dependents
  619. Nociceptin/orphanin FQ receptors modulate the discriminative stimulus effects of oxycodone in C57BL/6 mice
  620. Neuropsychopharmacological understanding for therapeutic application of morphinans
  621. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts
  622. Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents
  623. The Role of the Serotonin 2 Family of Receptors in cocaine-elicited and cocaine-conditioned Behaviors
  624. Innate cocaine-seeking vulnerability arising from loss of serotonin-mediated aversive effects of cocaine in rats
  625. The role of neuroscience in drug policy: promises and prospects
  626. GLP-1 and weight loss: unraveling the diverse neural circuitry
  627. Upregulation of nerve growth factor in central amygdala increases sensitivity to opioid reward
  628. Dopamine D3 receptor ligands: a patent review (2014–2020)
  629. CART peptides regulate psychostimulants and may be endogenous antidepressants
  630. The neuronal circuitry underlying the reinstatement of cocaine-seeking behavior in rats
  631. Neurobiology of cataplexy
  632. History use, and basic pharmacology of stimulants
  633. Expression and distribution of neuropeptide-expressing cells throughout the rodent paraventricular nucleus of the thalamus
  634. Serotonergic modulation of the behavioral and neurochemical effects of cocaine
  635. A mechanistic overview of approaches for the treatment of psychostimulant dependence
  636. Monoamine transporters and psychostimulant drugs
  637. Arc and homer 1a expression following intravenous administration of heroin and cocaine: a novel application of the catFISH technique
  638. Preclinical Models of Relapse to Psychostimulants Induced by Environmental Stimuli
  639. Gabapentinoid use disorder: Update for clinicians
  640. Antagonism of metabotropic glutamate group II receptors in the potential treatment of neurological and neuropsychiatric disorders
  641. Transcranial Magnetic Stimulation as a Tool to Promote Smoking Cessation and Decrease Drug and Alcohol Use
  642. Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists
  643. Methamphetamine Induces TET1- and TET3-Dependent DNA Hydroxymethylation of Crh and Avp Genes in the Rat Nucleus Accumbens
  644. Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction
  645. A Review of the Behavioral Effects of Serotonin (5-HT) 1B, 2A, and 2C Receptors on Psychostimulant Addiction-Like Behaviors in Animals
  646. The Role of Brain Reward Systems in Pathological Behavior: Cellular and molecular deconstruction of striatal adaptations
  647. CART peptide regulates psychostimulant-induced activity and exhibits a rate dependency
  648. Identifying Novel Roles for Peptidergic Signaling in Mice
  649. Deep TMS H7 coil: features, applications & future
  650. Transcranial magnetic stimulation of the medial prefrontal cortex for psychiatric disorders: a systematic review
  651. Chronic physical and vicarious psychosocial stress alter fentanyl consumption and nucleus accumbens Rho GTPases in male and female C57BL/6 mice
  652. Cue-elicited functional connectivity of the periaqueductal gray and tonic cocaine craving
  653. Mechanisms and treatments of drug consumption: A preclinical exploration in harm reducing pharmacotherapies for substance use disorders
  654. The role of stress in psychostimulant addiction: treatment approaches based on animal models
  655. Chronic phenmetrazine treatment promotes D2 dopaminergic and α2-adrenergic receptor desensitization and alters phosphorylation of signaling proteins and local …
  656. Voluntary cocaine or sugar intake induce neuroadaptations of the endocannabinoid system in reward-related brain regions
  657. Non-invasive brain stimulation modalities for the treatment and prevention of opioid use disorder: a systematic review of the literature
  658. Mechanism of Action of the Glucagon-like Peptide-1 analog Exendin-4 in the Reward System–A Preclinical Study in the Drug Addiction Field
  659. Systemic administration of anorexic gut peptide hormones impairs hedonic-driven sucrose consumption in mice
  660. Abstinence-induced nicotine seeking relays on a persistent hypoglutamatergic state within the amygdalo-striatal neurocircuitry
  661. Binge-like palatable food intake in rats reduces preproglucagon in the nucleus tractus solitarius
  662. Lateral Habenula 5-HT2C Receptor Function Is Altered by Acute and Chronic Nicotine Exposures
  663. Psychostimulants: basic and clinical pharmacology
  664. Silvia S. Martins, MD, PhD Julian Santaella-Tenorio, MSc
  665. Increase in cocaine-and amphetamine-regulated transcript (CART) in specific areas of the mouse brain by acute caffeine administration
  666. Immune signaling as a node of interaction between systems that sex-specifically develop during puberty and adolescence
  667. Rewiring the addicted brain: circuits-based treatment for addiction
  668. Intra-accumbal administration of shRNAs against CART peptides cause increases in body weight and cocaine-induced locomotor activity in rats
  669. Yohimbine depresses excitatory transmission in BNST and impairs extinction of cocaine place preference through orexin-dependent, norepinephrine …
  670. The addicted brain: why we abuse drugs, alcohol, and nicotine
  671. Role of serotonin in the regulation of the dynorphinergic system by a κ-opioid agonist and cocaine treatment in rat CNS
  672. Locomotor stimulant effects of novel phenyltropanes in the mouse
  673. cocaine and amphetamine-regulated transcript-containing neurons in the nucleus accumbens project to the ventral pallidum in the rat and may inhibit cocaine …
  674. Genome-edited skin epidermal stem cells protect mice from cocaine-seeking behaviour and cocaine overdose
  675. Director’s Report
  676. Clinical investigations of compounds targeting metabotropic glutamate receptors
  677. Substance Use Disorders and the Behavioral Effects of Novel and Existing Compounds
  678. The role of linagliptin, a selective dipeptidyl peptidase-4 inhibitor, in the morphine rewarding effects in rats
  679. Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice
  680. Involvement of a mesocorticolimbic subcircuit in the reinstatement of drug context-induced cocaine-seeking in rats
  681. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial
  682. CART peptide in the nucleus accumbens regulates psychostimulants: Correlations between psychostimulant and CART peptide effects
  683. Iptakalim as a human nicotinic acetylcholine receptor antagonist
  684. cocaine withdrawal alters the reward omission effect and enhances traits of negative urgency in rats across multiple days of testing
  685. Overexpression of Shati/Nat8l, an N-acetyltransferase, in the nucleus accumbens attenuates the response to methamphetamine via activation of group II mGluRs in …
  686. Role of Medial Prefrontal Cortical Group II Metabotropic Glutamate Receptor in the Development of cocaine Sensitization
  687. Glucagon-like peptide-1 analog exendin-4 ameliorates cocaine-mediated behavior by inhibiting toll-like receptor 4 signaling in mice
  688. Are pharmacokinetic approaches feasible for treatment of cocaine addiction and overdose?
  689. Neural Mechanisms of Addiction
  690. Chromatin immunoprecipitation assays revealed CREB and serine 133 phospho-CREB binding to the CART gene proximal promoter
  691. Exendin-4 increases absence-like seizures and anxiety–depression-like behaviors in WAG/Rij rats
  692. The lack of conditioned place preference, but unaltered stimulatory and ataxic effects of alcohol in mGluR3-KO mice
  693. Subcellular & subsynaptic localization of group I metabotropic glutamate receptors in the nucleus accumbens
  694. Subcellular and subsynaptic localization of group I metabotropic glutamate receptors in the nucleus accumbens of cocaine-treated rats
  695. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications
  696. A randomised, double-blind, sham-controlled study of left prefrontal cortex 15 Hz repetitive transcranial magnetic stimulation in cocaine consumption and …
  697. Glucagon-like peptide 1 in the brain: where is it coming from, where is it going?
  698. Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl) butyl)-4-(thiophen-3-yl) benzamides as selective dopamine D3 receptor ligands
  699. Linker Functionalization of a Bivalent Ligand for the Study of the 5-HT2AR/5-HT2CR Heterodimer
  700. Enzyme-therapy approaches for the treatment of drug overdose and addiction
  701. Interaction of dopamine and glutamate in the context of reward
  702. Lorcaserin bidirectionally regulates dopaminergic function site-dependently and disrupts dopamine brain area correlations in rats
  703. Regulation of CART peptide expression by CREB in the rat nucleus accumbens in vivo
  704. Effects of baclofen and phenmetrazine on neuronal signaling pathways implicated in psychostimulant addiction
  705. Cholinergic modulation of circuits
  706. Neural Plasticity in the Ventral Tegmental Area, Aversive Motivation during Drug Withdrawal and Hallucinogenic Therapy
  707. Neuroscience of behavioral and pharmacological treatments for addictions
  708. Addiction-related behavioral problems increase during the first six months of the Covid-19 pandemic
  709. Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics
  710. Dopamine neurotransmission in the ventral tegmental area promotes active forgetting of cocaine-associated memory
  711. Current Pharmaceutical & Clinical Research
  712. Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain—Reply
  713. Effect of baclofen on morphine-induced conditioned place preference, extinction, and stress-induced reinstatement in chronically stressed mice
  714. Metabotropic Glutamate Receptors in Amygdala Functions
  715. Effects of 5-HT2C receptor modulation and the NA reuptake inhibitor atomoxetine in tests of compulsive and impulsive behaviour
  716. Diazepam concurrently increases the frequency and decreases the amplitude of transient dopamine release events in the nucleus accumbens
  717. Repetitive transcranial magnetic stimulation: Re-wiring the alcoholic human brain
  718. GL Gessa (Cagliari)
  719. cocaine-and Amphetamine-Regulated Transcript (CART) Peptide and Drug Addiction
  720. Central amygdala CART modulates ethanol withdrawal-induced anxiety
  721. Amphetamine
  722. Catalytic activities of a highly efficient cocaine hydrolase for hydrolysis of biologically active cocaine metabolites norcocaine and benzoylecgonine
  723. Stimulation of serotonin2C receptors elicits abnormal oral movements by acting on pathways other than the sensorimotor one in the rat basal ganglia
  724. Effects of 5-HT1A, 5-HT2A and 5-HT2C receptor agonists and antagonists on responding for a conditioned reinforcer and its enhancement by methylphenidate
  725. “This Isn’t the South Bronx” Race, Criminality, and Disability in the Contemporary Opioid Epidemic
  726. Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight
  727. Orexin receptors within the nucleus accumbens shell mediate the stress but not drug priming-induced reinstatement of morphine conditioned place preference
  728. CART-containing neurons in the nucleus accumbens project to the ventral pallidum in the rat and may inhibit cocaine-induced locomotion
  729. Implications of prenatal exposure to synthetic corticosteroid in the mesolimbic reward pathway
  730. Soy Isoflavone extract does not increase the intoxicating effects of acute alcohol ingestion in human volunteers
  731. Kinetic characterization of an efficient cocaine hydrolase against toxic metabolites of cocaine
  732. A commentary on gender does not matter: add-on repetitive transcranial magnetic stimulation treatment for female methamphetamine dependents
  733. The Therapeutic Potential of
  734. The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
  735. How fixed prices of heroin coexist with variations in consumer demand within a local heroin market LD Hoffer, SK Koester, A. Ben Abdallah and LB Cottler …
  736. The role of metabotropic glutamate type 5 receptors in amphetamine sensitization: Investigations in humans and rodents
  737. Long-term functional alterations following prenatal GLP-1R activation
  738. Alternative formats
  739. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality
  740. cocaine-and-Amphetamine Regulated Transcript (CART) peptide attenuates dopamine-and cocaine-mediated locomotor activity in both male and female rats: lack of …
  741. Glial cells and their contribution to the mechanisms of action of cannabidiol in neuropsychiatric disorders
  742. Brain Stimulation Methods for Substance Use Disorders
  743. Effects of escitalopram on attentional bias to cocaine-related stimuli and inhibitory control in cocaine-dependent subjects
  744. Unravelling the role of the cerebellum in drug addiction. Cerebellum-prefrontal networks in drug-induced preference memory
  745. The central serotonin2B receptor as a new pharmacological target for the treatment of dopamine-related neuropsychiatric disorders: Rationale and current status of …
  746. An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity
  747. Localization and targeting of GIRK channels in mammalian central neurons
  748. STUDY#: NIDA-CPU-0003
  749. Effects of 5-HT, 5-HT and 5-HT receptor agonists and antagonists on responding for a conditioned reinforcer and its enhancement by methylphenidate.
  750. Neurochemical evidence that cocaine-and amphetamine-regulated transcript (CART) 55–102 peptide modulates the dopaminergic reward system by decreasing the …
  751. Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anticocaine medications
  752. Effects of sex and prenatal stress on vulnerability to drugs
  753. Marijuana use among adolescents is associated with deleterious alterations in mature BDNF
  754. Framing the Future of Nicotine and Tobacco Research in the New Millennium: Sixth Annual Meeting Society for Research on Nicotine and Tobacco Arlington, VA, USA …
  755. Learning to Be a cocaine Addict: Behavioral, Pharmacological, and Molecular Characterization in Initial Learning of cocaine-Environment Associations
  756. Learning to be a cocaine addict: behavioral, pharmacological, and molecular characterization of individual differences in initial learning of cocaine-environment …
  757. Postnatal developmental profile of urocortin 1 and cocaine-and amphetamine-regulated transcript in the perioculomotor region of C57BL/6J mice
  758. Chairs: Thomas R. Kosten and Staci Gruber
  759. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats
  760. A motivational and neuropeptidergic hub: anatomical and functional diversity within the nucleus accumbens shell
  761. Interesting rTMS Results in Healthy People
  762. Expression of cocaine-and amphetamine-regulated transcript in the rat forebrain during postnatal development
  763. Comparison of STAT3 Phosphorylation Between IDI Versus INI Isoforms and Acute Versus Chronic Treatment of the Human Serotonin 2C Receptor
  764. Activation of mGluR2/3 following stress hormone exposure restores sensitivity to alcohol in rats
  765. Nucleus accumbens cocaine-amphetamine regulated transcript mediates food intake during novelty conflict
  766. Scanning Sex, Stress and Substance Abuse Susceptibility: Neural Correlates of Vulnerability to Abuse Drugs.
  767. Effects of non-invasive brain stimulation on stimulant craving in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis
  768. Nicotine Withdrawal and Deficits in Cognitive Flexibility: Possible Ties to Aberrations in Frontostriatal BDNF Signaling
  769. Functional and structural brain abnormalities in substance use disorder: A multimodal meta‐analysis of neuroimaging studies
  770. Utilization of Propensity Score Weighting and Targeted Maximum Likelihood Estimation in the Post Hoc Analysis of a Randomized Controlled Trial for the Treatment of …
  771. Central control of feeding behavior by the secretin, PACAP, and glucagon family of peptides
  772. Contributions to the Epidemiology of cocaine Dependence: Novel Estimates of Transition Probabilities Among Subgroups of cocaine Initiates
  773. Progesterone serum levels correlate negatively with craving in female postmenopausal in-patients with alcohol use disorder: A sex-and menopausal status-separated …
  774. Translational Neuroscience Unit Donders Institute Nijmegen
  775. Blockade of group II metabotropic glutamate receptors produces hyper-locomotion in cocaine pre-exposed rats by interactions with dopamine receptors
  776. Neuromodulating the performance monitoring network during conflict and error processing in healthy populations: Insights from transcranial electric …
  777. Potential antidepressant role of neurotransmitter CART: implications for mental disorders
  778. Sexual motivation in male rats is modulated by tropomyosin receptor kinase B (TrkB).
  779. Cognitive impairment: quantification and possibilities for pharmacological treatment
  780. Considerations for single-versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathy
  781. The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin
  782. Pregabalin abuse and addiction
  783. Assessment of the Possible Oxidative Hepatotoxicity Induced by Cannabis and Pregabalin in Rats
  784. The discovery and development of liraglutide and semaglutide
  785. Differential Modulation Of Oxycodone Reward And Analgesia By A Cannabinoid Derivative
  786. Alleviation of depression by glucagon-like peptide 1 through the regulation of neuroinflammation, neurotransmitters, neurogenesis, and synaptic function
  787. The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites
  788. Leptin receptor neurons in the mouse hypothalamus are colocalized with the neuropeptide galanin and mediate anorexigenic leptin action
  789. Design, synthesis, and evaluation of functionalized 5-(4-arylpiperazin-1-yl)-N-arylpentanamides as selective dopamine D3 receptor ligands
  790. Alkaloids from the genus Duguetia
  791. Prevalence and risk factors of pregabalin misuse among patients with substance use disorder
  792. Drug-Seeking Behavior Is Significantly Attenuated in Nutritionally Supplemented cocaine Withdrawn Sprague-Dawley Rats
  793. Schwann cell autocrine and paracrine regulatory mechanisms, mediated by allopregnanolone and BDNF, modulate PKCε in peripheral sensory neurons
  794. Neural correlates of age-related memory decline and sensitivity to BDNF gene delivery
  795. Inhibitory role of inducible cAMP early repressor (ICER) in methamphetamine-induced locomotor sensitization
  796. Design, Synthesis, And Evaluation of Functionalized Diamino-butylbenzamides As Selective Dopamine D3 Receptor Ligands
  797. The roles of serotonin in neuropsychiatric disorders
  798. Effects and mechanisms of 3α, 5α,-THP on emotion, motivation, and reward functions involving pregnane xenobiotic receptor
  799. Synthesis of functionalized 5-(4-arylpiperazin-1-yl)-N-arylpentanamides and their evaluation as D3 receptor ligands
  800. Pharmacological evidence that 5-HT2C receptor blockade selectively improves decision making when rewards are paired with audiovisual cues in a rat gambling …
  801. Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014)
  802. Misuse of pregabalin: case series and literature review
  803. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial
  804. Effects of cyclotraxin-b treatment on endometriotic lesion survival in an immunocompromised mouse model
  805. Studies To Examine Potential Tolerability Differences between the 5-HT2C Receptor Selective Agonists Lorcaserin and CP-809101
  806. Acute pharmacological profile of 2C-B-Fly-NBOMe in male Wistar rats—pharmacokinetics, effects on behaviour and thermoregulation
  807. Sex differences in invasive and noninvasive neurotechnologies
  808. Effect of yohimbine stress on reacquisition of oxycodone seeking in rats
  809. Obesity and dietary added sugar interact to affect postprandial GLP-1 and its relationship to striatal responses to food cues and feeding behavior
  810. Evaluating Repetitive Transcranial Magnetic Stimulation to Reduce Opioid Cravings in Opioid Use Disorder
  811. GRM7 gene mutations and consequences for neurodevelopment
  812. Molecular and behavioral responses of zebrafish embryos/larvae after sertraline exposure
  813. An overview of similarities and differences in metabolic actions and effects of central nervous system between glucagon-like peptide-1 receptor agonists (GLP-1RAs) …
  814. Glutamate and MDMA Neurobehavioral Toxicity
  815. Optimizing Individual Targeting of Fronto-Amygdala Network with Transcranial Magnetic Stimulation (TMS): Biophysical, Physiological and Behavioral Variations in …
  816. Ligand-directed serotonin 5-HT2C receptor desensitization and sensitization
  817. Extremely low frequency electromagnetic field exposure and restraint stress induce changes on the brain lipid profile of Wistar rats
  818. Natural Striatal Signaling Dynamics During Food Approach
  819. Comparing Chronic Treatments of the INI and VSV Isoforms of the Human Serotonin 2C Receptor Impacting Phosphorylation of STAT3
  820. PRACTICE OF ISLAMIC MICROFINANCE BY DIFFERENT NON-GOVERNMENT ORGANIZATION’S IN BANGLADESH: AN EMPIRICAL EVIDENCE
  821. Effects of isovaline and involvement of metabotropic group ii glutamate receptors
  822. Development of an Animal Phenotype of Gambling Disorder: Chronic Reward Uncertainty Induces a Gambling Disorder-like State of Sensitization and …
  823. The neurotoxic effect of long-term use of high-dose Pregabalin and the role of alpha tocopherol in amelioration: implication of MAPK signaling with oxidative stress …
  824. Preclinical Development of a Novel Serotonin Receptor Modulator for Fragile X Syndrome
  825. Accelerated repetitive transcranial magnetic stimulation does not influence grey matter volumes in regions related to alcohol relapse: An open-label exploratory study
  826. The contribution of microglia to early synaptic compensatory responses that precede β-amyloid-induced neuronal death
  827. Identification and characterization of a novel, conserved metallo-β-lactamase regulator of dopamine and glutamate signaling
  828. Leptin Regulates Nutrient Reward Via Galanin and Orexin Neurons
  829. Dopamine depresses melanin concentrating hormone neuronal activity through multiple effects on α2-noradrenergic, D1 and D2-like dopaminergic receptors
  830. The Effects of Liraglutide on the Learned Control of Appetitive Behavior
  831. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction
  832. CHAPITRE 7. MODULATION OF GLUTAMATE RECEPTORS IN DYSKINETIC MPTP MONKEYS RECEIVING A UNILATERAL SUBTHALAMOTOMY
  833. Physiological and Pathophysiological Aspects of 5-HT2c Receptors in Basal Ganglia
Related Posts

Ergogenic Agents (Increase Athletic Performance)

Lowering Cholesterol Thru Fasting, Diet & Medicinal Plants

Remyelination

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping